Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
SK Hynix Shares Fall as Workers Reject Wage Deal 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Nvidia Options Price in $280 Billion Earnings Swing 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Add as a preferred source on Google
BURLINGTON, Mass., April 30, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, May 8, 2018. Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on business operations.
The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #2880817. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
